BioCryst Pharmaceuticals, Inc.
BCRX
$8.39
-$0.17-1.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.85% | 41.67% | 36.00% | 29.92% | 24.65% |
| Total Other Revenue | -- | -88.34% | -8.93% | -36.35% | -58.49% |
| Total Revenue | 45.85% | 41.67% | 36.00% | 29.92% | 24.65% |
| Cost of Revenue | -7.08% | -15.83% | -13.70% | -11.87% | -13.43% |
| Gross Profit | 105.31% | 129.81% | 129.83% | 131.90% | 146.40% |
| SG&A Expenses | 33.98% | 28.47% | 24.70% | 25.14% | 26.61% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.01% | 6.83% | 5.36% | 5.52% | 4.32% |
| Operating Income | 197.85% | 139.09% | 97.43% | 66.67% | 50.93% |
| Income Before Tax | 78.02% | 75.46% | 61.56% | 47.08% | 38.89% |
| Income Tax Expenses | 723.58% | 57,100.00% | 521.61% | -116.95% | -118.74% |
| Earnings from Continuing Operations | 75.53% | 74.37% | 60.77% | 47.61% | 39.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.53% | 74.37% | 60.77% | 47.61% | 39.88% |
| EBIT | 197.85% | 139.09% | 97.43% | 66.67% | 50.93% |
| EBITDA | 208.60% | 144.11% | 100.49% | 68.35% | 52.28% |
| EPS Basic | 76.38% | 75.80% | 63.50% | 51.58% | 43.50% |
| Normalized Basic EPS | 80.85% | 72.19% | 57.85% | 46.44% | 36.91% |
| EPS Diluted | 75.82% | 75.86% | 63.59% | 51.54% | 43.47% |
| Normalized Diluted EPS | 80.49% | 72.17% | 57.85% | 46.44% | 36.91% |
| Average Basic Shares Outstanding | 3.63% | 5.51% | 7.56% | 8.83% | 7.03% |
| Average Diluted Shares Outstanding | 5.71% | 6.33% | 7.56% | 8.83% | 7.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |